| Zylet (U.S.N.L.M.) | |
|---|---|
| Dosing | q1-2hr in first 24-48 hrs if needed, then q4-6hr x 2 wks. Taper. For chronic lid margin disease "pulse" 1 week qid dosing to treat recurrences. |
| Chem Specs | Tobramycin 0.3%, Loteprednol etabonate 0.5% |
| Quantities | 2.5, 5, 10ml |
| Cost | 335.00/5ml |
| Class | aminoglycoside, ester steroid |
| Action | Aminoglycosides prevent bacterial protein synthesis. Corticosteroids inhibit arachidonic acid release. Aminoglycosides prevent bacterial protein synthesis. Corticosteroids inhibit arachidonic acid release. |
| Activity | Active against a wide variety of gram-negative and gram-positive bacteria including some penicillin-resistant and gentamicin-resistant strains. Active against a wide variety of gram-negative and gram-positive bacteria including some penicillin-resistant and gentamicin-resistant strains. |
| Usage | Indicated for steroid-responsive inflammatory conditions where superficial bacterial infection or a risk of bacterial infection exists. Indicated for steroid-responsive inflammatory conditions where superficial >bacterial infection or a risk of bacterial infection exists. |
| Off label usage for blepharitis related dry eye and GPC (see literature for details). | |
| Contraindications | Acanthamoeba, most viral, mycobacterial, and fungal disease. Hypersensitivity to this or other aminoglycosides, corticosteroids, or any components of the medication. Acanthamoeba, most viral, mycobacterial, and fungal disease. Hypersensitivity to this or other aminoglycosides, corticosteroids, or any components of the medication. |
| Pediatric use | Effectiveness in pediatric patients under age 6 has not been established. |
| Pregnancy | Embryotoxic and teratogenic in animals at 35 times the normal human oral dose. |